1. Home
  2. About Us
  3. Who We Are
  4. Management Team
  5. Sergio Dompé

Sergio Dompé

Executive President

Born in Milan in 1955, Sergio Dompé is an entrepreneur in the pharmaceutical and biotechnological industries and President of Dompé, a pharmaceutical group developing innovative therapeutic solutions for rare and orphan diseases. He has been awarded honorary doctorates in Biotechnology with specialization in pharmaceutics (Bologna, 1996), Medical Biotechnology (L’Aquila, 2005) and Pharmacy (Urbino, 2010). Among the first in Italy to grasp the true value of biotechnology applied to human health, he has developed an extensive network of partnerships with the most significant research centres for diseases in Dompé’s main therapeutic fields.

In 2016, he funded and established Movendo, an innovative medical company sparked by an idea by the Italian Institute of Technology: to develop the most advanced technologies at the service of mankind and products in the field of physical movement rehabilitation. In the same year, he received the Prize of the Foundation Aiuto per la Ricerca sulle Malattie Rare (A.R.M.R.), regularly awarded to those who distinguish themselves in the research field. In 2017 he was awarded the Guido Carli prize.

Institutional offices held:

  • From 1998 to 2004: President of Assobiotec
  • Since 2004, anchor investor in Philogen, a leader in the research and development of antibodies
  • From 2005 to 2011: President of Farmindustria
  • From 2006 to 2011: Chairman of the Evaluation Committee of the CNR (Consiglio Nazionale delle Ricerche, National Research Council)
  • From 2007 to 2015: member of the Board of the IIT (Italian Institute of Technology) Foundation
  • From 2014 to 2016: member of the Patent Experts Committee of the CNR
  • From 2014 to 2016: member of the Board of Regency of the Bank of Italy (Milan office)
  • Since 2015: member of the General Council of Confindustria as representative of Farmindustria
  • Since 2016: Censor of the Bank of Italy (Milan office)
  • Since 2019: Vice President of Assolombarda with delegated powers over Life Sciences
  • 2020: Chairman of the 2021 B20 Life Sciences task-force
  • Since 2023: President of the Leonardo Committee